Heart Disease News and Research

Latest Heart Disease News and Research

VIVUS' Phase 3 studies find Qnexa effective in tackling obesity

VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.

9 Sep 2009

International summit on the H1N1 influenza pandemic and critical business preparedness

The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota is convening an international summit on the H1N1 influenza pandemic and critical business preparedness.

9 Sep 2009

Top 10 U.S.hospitals prefer Arctic Sun temperature management system

The number of Arctic Sun(R) users among hospitals ranked top 20 jumped to 90 percent this year from 72 percent last year, Medivance announced today. All top 10 "best hospitals" prefer the ease and safety of its advanced non-invasive method for rapid, controlled temperature reduction followed by slow rewarming.

9 Sep 2009

Neuralstem's patent on neural stem cell transplantation approved

Neuralstem, Inc. today announced that it has received notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent entitled “Transplantation of Human Neural Cells For Treatment Of Neurodegenerative Conditions,” number 11/281,640.

9 Sep 2009

Campaign launched to tackle childhood obesity

Urging children to get at least 60 minutes of physical activity each day, Pennsylvania Health Secretary Everette James and Education Secretary Gerald Zahorchak today helped to kick off the NFL Play 60 national youth health and fitness campaign.

9 Sep 2009

Sequoia Hospital completes 1000 atrial fibrillation ablation procedures

Sequoia Hospital announced that the Cardiac Arrhythmia Program has completed 1,000 atrial fibrillation (A-Fib) ablation procedures, making it the highest total volume A-Fib ablation institution currently performing ablations in Northern and Central California.

9 Sep 2009

International Institute of Biomedical Sciences and Technology established for a global research initiative

Upstate Medical University in Syracuse, New York, the Technion-Israel Institute of Technology in Haifa, Israel, and National Cheng Kung University in Tainan City, Taiwan, have announced the creation of the International Institute of Biomedical Sciences and Technology that will facilitate the collaboration of research across three continents and accelerate the development of novel bioengineering, diagnostic and biomedical products for the treatment and cure of disease, officials said today.

9 Sep 2009

Psoriasis Walk organized to support the research and education programs of Psoriasis Cure Now

The first-ever New Jersey Psoriasis Walk will take place in Paramus this Saturday, September 12, 2009, at beautiful Van Saun Park. The walk, to support the research and education programs of the nonprofit Psoriasis Cure Now, will include entertainment, information booths on psoriasis treatments, and a chance to meet and learn from others living with psoriasis and psoriatic arthritis. Janine Natoli of Little Falls is volunteer Chair of the NJ Psoriasis Walk, on the Web at http://www.PsoriasisWalkNJ.org.

9 Sep 2009

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.

9 Sep 2009

Consortium awarded $3.75M to set up an AIDS research center in Chicago

The National Institutes of Health (NIH) has awarded a consortium of Chicago-based institutions, led by Rush University Medical Center, a five-year, $3.75-million grant to establish a Developmental Center for AIDS Research, creating a comprehensive research infrastructure to spur basic science, clinical studies and translational research in the prevention, detection and treatment of HIV infection and AIDS.

9 Sep 2009

Lack of physical activity is linked to childhood obesity

It's the start of another school year and Canadian physiotherapists are taking this opportunity to talk tough about the epidemic of overweight and inactive children in this country. According to Statistics Canada about 25 percent of Canadian children are overweight. The Active Healthy Kids Canada 2009 Report Card found that only 13 percent of children and youth are getting the 90 minutes of physical activity recommended by Canada's Physical Activity Guide.

9 Sep 2009

Prostate cancer treatment options discussed in a study

A new study in the Journal of the American Medical Association (JAMA) appears to support the theory outlined in earlier studies that men with more advanced forms of prostate cancer don't benefit from a combination of hormone and radiation therapy.

9 Sep 2009

New findings may help identify treatments for diabetes and hyperinsulinemia

By investigating a rare and severe form of diabetes in children, University of Iowa researchers have discovered a new molecular mechanism that regulates specialized pancreatic cells and insulin secretion. The mechanism involves a protein called ankyrin, which UI researchers previously linked to potentially fatal human heart arrhythmias.

9 Sep 2009

Free pedometers from Humana for spectators at the Utah Championship in Sandy

Have you ever wondered how many steps you take during a round of golf? You can find out for sure — and maybe even win a prize — during the Nationwide Tour’s Utah Championship, thanks to a promotion from Humana Inc. (NYSE: HUM), the official health benefits company of the PGA TOUR.

9 Sep 2009

Humana Military announces the URAC re-accreditation for its Case Management Program

Humana Military Healthcare Services, a wholly owned subsidiary of Humana Inc. (NYSE: HUM), recently received re-accreditation for its Case Management Program from URAC, a Washington, D.C.-based health care accrediting organization that establishes quality standards for the industry.

9 Sep 2009

European Dynamic Annuloplasty Activation study completes patient enrollment

MiCardia (MiCardia Corporation, Irvine, California) today announced the completion of enrollment in its European “DYANA” (Dynamic Annuloplasty Activation) study, designed to support submission for CE mark of the firm’s Dynaplasty technology in Europe.

9 Sep 2009

Nutrisystem D program helps overweight type 2 diabetic people lose weight

Results from a clinical study conducted at the Temple University School of Medicine and published today in the journal Postgraduate Medicine(1), show that a pre-packaged, portion controlled meal plan helped overweight individuals with type 2 diabetes lose significantly more weight and reduce their A1C test scores (a 90-day measure of blood sugar control) by almost a full point greater than those following a standard hospital-based diabetes support and education program, according to the findings.

9 Sep 2009

Regular usage of CGM devices help manage diabetes

The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors - six days per week or more - rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices - including experiencing fewer low blood sugar emergencies.

9 Sep 2009

FDA approves the distribution of IMRISNV and IMRIScardio systems

IMRIS Inc. ("IMRIS" or the "Company") today announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA), permitting the Company to market its newest products, IMRISNV and IMRIScardio in the United States.

9 Sep 2009

Research study examines the depression rate in chronic kidney disease patients

One in five patients with chronic kidney disease is depressed, even before beginning long-term dialysis therapy or developing end-stage renal disease, UT Southwestern Medical Center researchers have found.

9 Sep 2009